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The second step in vitro trial of Ankaferd® Bloodstopper®:
comparison with other hemostatic agents
Emre HURİ1, Kadir Turgay AKGÜL1, Mehmet Özgür YÜCEL1, Hesna Müzeyyen ASTARCI2,
Hüseyin ÜSTÜN2, Rüştü Cankon GERMİYANOĞLU1
Aim: To investigate the efficacy of Ankaferd Bloodstopper (ABS) and compare ABS with the other hemostatic agents still
used in urologic surgery.
Materials and methods: Forty Wistar rats were divided into 5 groups: Group T (traditional), partial nephrectomy (PN)
with hilar control as per the conventional technique; Group G (Glubran 2), conventional PN followed by the application
of Glubran 2; Group F (FloSeal), FloSeal application to the resected area of the kidney; Group C (Celox), Celox was
applied; Group A (ABS), Ankaferd was used. Warm ischemia time (WIT) and hemostasis time (HT) were recorded and
histopathologic features were compared among the groups.
Results: In Group A, a significant decrease in WIT was detected while the difference was significant (P < 0.001). Statistical
analysis confirmed that the evaluation of HT (in seconds) returned similar results to those seen in WITs among all
groups. In Group A, decreased HT was confirmed in comparison to Group T while HT increased in comparison to the
other groups (G, C, and F) (P < 0.001). Increased fibrosis and adhesion were shown in Group F while significant
erythrocyte aggregation and microvascular proliferation were observed in Groups G, F, and A (P < 0.001).
Conclusion: A novel hemostatic agent, ABS, is as effective as other licensed hemostatic agents with comparable WIT and
HT and better results in terms of histopathologic findings.
Key words: Hemostatic agents, hemostasis, comparison, partial nephrectomy

Ankaferd bloodstopper ikinci basamak in vitro çalışması:
Diğer hemostatik ajanlarla karşılaştırma
Amaç: Bu çalışmada Ankaferd BloodStopper’ın etkinliği diğer hemostatik ajanlar ile karşılaştırılarak yapılmaya
çalışılmıştır.
Yöntem ve gereç: Kırk Wistar rat beş gruba ayrıldı. Bu gruplar: T grubu (traditional), hilar kontrol ile parsiyel nefrektomi
yapılan, G grubu (Glubran 2) konvansiyonel parsiyel nefrektomi sonrası Glubran 2 uygulanan, F grubu eksize edilen
böbrek alanına FloSeal uygulanan, C grubu hemostatik ajan olarak Celox kullanılan, A grubu ise yeni bir hemostatik ajan
olan Ankaferd (Ankaferd-ABS) kullanılan gruplar olarak belirlendi. Sıcak iskemi süreleri ve hemostaz zamanları kayıt
edildi. Gruplar arasındaki histopatolojik özellikler karşılaştırıldı. Istatistiksel analiz için Kruskal-Wallis ve Mann-Whitney
U testleri kullanıldı.
Bulgular: A grubunda ölçülen sıcak iskemi süresi anlamlı derecede düşük olarak saptanırken diğer gruplarla fark anlamlı
idi (P < 0,001). A grubunda T grubuyla karşılaştırıldığında azalan hemostaz zamanın diğer gruplarla karşılaştırıldığında
artmış olduğu belirlendi (P < 0,001). A grubunda diğer gruplarla karşılaştırıldığında anlamlı derecede fibrozis, adhezyon
ve kalsifikasyon oluşmadığı gözlendi. F grubunda fibrozis ve adhezyonun artmış olduğu gösterildi. A, F ve G gruplarında
eritrosit agregasyonu ve mikrovasküler proliferasyonun anlamlı olarak yüksek olduğu gözlendi (P < 0,001).
Sonuç: Yeni çıkan bir hemostatik ajan olan Ankaferd, diğer lisanslı hemostatik ajanlar kadar etkilidir, sıcak iskemi süresi
ve hemostaz süreleri için karşılaştırılabilir ve histopatolojik olarak da iyi sonuçlara sahiptir.
Anahtar sözcükler: Hemostatik ajanlar; hemoztaz; karşılaştırma, parsiyel nefrektomi
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Introduction
In recent literature, many technical methods have
been introduced for controlling bleeding during the
partial nephrectomy. In our previous study, we
demonstrated the efficacy of Ankaferd Bloodstopper
(ABS) in a rat partial nephrectomy model (1).
However, the most important factor for preventing
renal parenchymal damage during partial
nephrectomy is to decrease the warm ischemia time
(WIT). In addition, new emphasis is being given to
the importance of speedy hemostasis in partial
nephrectomy. According to the urology guidelines of
AUA and EAU, this surgery should be chosen,
particularly for especially small renal tumors of less
than 7 cm (2). In the conventional technique, either
laparoscopically or open, hilar vascular control, repair
of the collecting system, blood vessels, and capsular
closure with Surgicel® bolsters are required (3).
Recently, the use of hemostatic agents has become
more popular, especially in the field of urological
surgery. Many materials have been proposed as a way
to stop hemorrhage during kidney surgery (4). In
particular, an increase in the demand for hemostatic
agents has followed an increased demand for
laparoscopic kidney surgery (5). The difficulty of
hemostasis in laparoscopic partial nephrectomy
(LPN) has led to technical concerns over this type of
surgery (6). In 1909, Bergel first described the use of
dry plasma to facilitate hemostasis (7). Fibrin glues,
absorbable fibrin adhesive, synthetic hydrogel
polymer, and liquid albumin-indocyanine green
solder were subsequently developed to use for the
same purpose as a sealing agent (8-11).
ABS is a unique folkloric medicinal plant extract
that has historically been used in Turkish traditional
medicine. ABS is composed of a mixture of 5 plants,
each with some effect on endothelium, blood cells,
angiogenesis, cellular proliferation, vascular
dynamics, and cell mediators (12). In this study, we
aimed to compare the efficacy of ABS with other
hemostatic and sealant agents (Glubran 2, FloSeal,
and Celox) that have already been licensed for use in
controlling kidney surgery bleeding.
Materials and methods
Study protocol
This study was approved by the local animal
review and ethics committee and the research council
8

at Ankara Training and Research Hospital. A total of
40 Wistar rats weighing 200 to 240 g were divided into
5 groups and underwent right lower pole PN. The
animals were fed into separate cages in which the
temperature was 22 °C. Targeted excised tissue was
2
determined to be approximately 1 cm in each rat. The
PN techniques of the groups were standardized and
groups were determined according to the type of
hemostatic agent used during the operation. Group T
(traditional) (GT) underwent right PN with hilar
vascular control including intracorporeal suturing of
the renal parenchyma and collecting duct. Group G
(Glubran 2) (GG) underwent conventional PN with a
Glubran 2 application. Group F (Floseal) (GF)
received an application of Floseal to the renal
parenchyma and collecting duct with hilar control. In
Group C (Celox) (GC), the PN and Celox application
were performed with hilar control. In Group A
(Ankaferd) (GA), Ankaferd was applied to the
resected tissue following the PN. In the first month
following scarification, the right nephrectomy was
performed. Gross specimens and histological sections
were blindly evaluated by 2 pathologists (HU, MA).
Sections were stained with hematoxylin and eosin.
Surgical procedure
After administering a prophylactic single dose
broad-spectrum antibiotics (sulbactam-ampicillin
intramuscular), general anesthesia with the
combination of ketamine HCl (40 mg/kg, ParkeDavis)
and xylazine HCl (10 mg/kg, Bayer, Germany), a
midline incision was made in the abdomen after
sterilization and draping. The right kidney was
completely mobilized. The right renal artery and vein
were occluded with a Rommel vascular clamp to
achieve hilar control. The lower third of the right
kidney was resected in guillotine fashion with a single
stroke of an amputating knife. The rats were
randomized for surgical technique according to the
groups. After the procedure, sponges were used to
collect all visible clots and blood, and the kidney was
replaced in the renal fossa.
Hemostatic techniques and identification of
hemostatic agents
In Group T, bimanual pressure was applied to the
amputated renal margin by the surgical assistant.
Segmental vessels and the collecting system were
repaired with absorbable sutures (3/0 polyglycolic
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acid). Neither sponges nor Surgicel® were used. As an
alternative to the traditional method, 4 types of
hemostatic agents (Glubran 2, Floseal, Celox, and
ABS) were used in a similar fashion on the resected
bleeding area in order to promote active hemostasis.
Glubran 2: Includes N-butyl-2-cyanoacrylate and
methacryloxysulfolane (NBCA MS) as a sealant agent.
Application of sealant to the excised renal surface has
been designed for 1 cc Glubran 2 dribbled onto the
whole bleeding area. The application should be done
when the bleeding starts from the tissue. Afterward,
the freezing of the agent was observed and the
hemostatic effect of Glubran 2 was evaluated.
FloSeal: This gelatin matrix hemostatic sealant was
applied to the resected area with its own application
device. The sponge embedded with isotonic NaCl was
used for manual compression to promote active
hemostasis.
Celox: A new chitosan granular dressing (CELOX
[CX], SAM Medical Products, Newport, OR, USA)
that reports success in controlling hemorrhage. This
agent is a fine granular product that works by
interacting directly with red blood cells and platelets
to form a cross-linked barrier clot, independent of
native factors. Celox was applied by pouring the
contents of one package into the wound.
Ankaferd® BloodStopper®: ABS is a hemostatic
agent including unique folkloric medicinal plant
extracts that has historically been used in Turkish
traditional medicine. A dosage of 2 cc of the injectable
form of ABS was applied to the amputated renal
margin slowly until the bleeding stopped. Afterwards,
a compress was applied to the resected surface for 23 min. Immediate application of the product to the
bleeding area is the major factor for effective
hemostasis with Ankaferd.
Objective parameters
WIT was measured from the initial occlusion of
the hilar vessels until the final release of the right renal
vessels. Hemostasis time (HT) was determined from
the first observation of bleeding, through the
application of the hemostatic agent until active
hemostasis. Urine extravasation, adherence to
adjacent organs and infection at the operated renal
margin were evaluated. Pathological specimens were
evaluated with emphasis on the presence or absence of

giant cell reaction, intestinal metaplasia, acute
inflammation, foreign material reaction, fibrosis,
adhesions, necrosis, fistula, erythrocyte aggregation,
microvascular proliferation, fibroblastic activation,
siderophages, glomerular necrosis, and calcification.
Our team used the pathological scoring system
detailed in our previous study.
Statistical analysis
Results were analyzed with SPSS® 15.0 for
Windows®. Definitive statistics were determined as
the mean ± standard deviation (SD), minimum,
maximum, and percent. Kruskal-Wallis and MannWhitney U-tests were used to evaluate significance
among the groups. The post hoc Bonferroni test was
also used to correct the significance level in subgroup
comparisons. P value was determined significant at <
0.05.
Results
A total of 40 open right lower-pole partial
nephrectomies were performed and major bleeding
was induced in each case. The rats used for this
experimental study had similar morphometric
characteristics in body and kidney shape. The mean
kidney size was 2 × 2.5 × 0.5 cm. The resected lower
pole kidney tissues were also similar in size and shape,
2
approximately 1 cm . All animals survived during the
operation and postoperative period.
Operative findings
Warm ischemia time (WIT) (in seconds) was
determined for the groups as follows: Group T, 150.4
(SD: 10.2); Group G, 43.3 (SD: 1.7); Group F, 52.1 (SD:
1.7); Group C, 66.6 (SD: 2.2); and Group A, 81.5 (SD:
6.5). Among the groups, there were significant
differences (95% CI) (P < 0.001) (Figure 1A). In
Group A, a significant decrease in WIT was detected
while the difference compared with the other groups
was also significant (P < 0.001). The evaluation of
hemostasis time (HT) (in seconds) among the groups
yielded results statistically similar to those of the
WITs. Results for HT were as follows: Group T, 140.1
(SD: 10.2); Group G, 32.9 (SD: 1.2); Group F, 40.9 (SD:
1.1); Group C, 55.8 (SD: 1.8); and Group A, 70.1 (SD:
6.6), and were detected with significant differences
(95% CI) (P < 0.001) (Figure 1B). In Group A,
9
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Figure 1. Warm ischemia times (WITs) of the groups.

Figure 2. Hemostasis times (HTs) of the groups.

decreased HT was confirmed when compared with
Group T while increased HT was detected in
comparison with the other groups (G, C, and F) (P <
0.001). Hemostatic efficacy was observed
macroscopically for each rat in the groups and the
macroscopic appearance of the kidneys following
application of each hemostatic agent is shown in
Figure 2 (A-E). Determination of the surgical effect
of hemostatic agents during the operation is shown in
the Table. Blood loss could not be evaluated
objectively due to the small kidney size and resected
tissue. There were no significant intraoperative
complications.

surfaces showed irregular shape and hardness. In
Group G, the appearance of Glubran was observed on
the resected area and minimal adhesion occurred. In
Group F, good biocompatibility of FloSeal and
restoration of resected tissue were observed with
increased perirenal adhesion. In Group C, the
resorption of Celox and absence of tissue reaction
were confirmed. In Group A, ABS kidneys were all in
good condition, especially in the resected area,
although redness and gelatinous, wealthy tissue were
observed in the transected kidney. No hematoma,
urinoma, or urine leakage was seen in any of the
groups.
Histopathologic findings of specimens

Scarification findings
For each group, macroscopic examination was
performed. In Group T, increased adherence to the
adjacent tissue was observed and the resected renal

Fibrosis, adhesion, and calcification were not
significantly demonstrated in Group A compared
with the other groups (P < 0.001). Increased fibrosis

Table. The determination of surgical effect of hemostatic agents during the operation.
Hemostatic Agent
Glubran 2
FloSeal
Celox
Ankaferd BloodStopper
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Hemostatic Effect (macro) onto the resected kidney area
Easy application, no need for compression, very adhesive to adjacent tissue,
one thin layer provides the haemostatic effect
Special device used, compression required
Safe for adjacent tissue, easy and generous application, granular fashion, compression required
The formation of aggregate (protein network), ruddy surface and
compression generally required
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and adhesion were shown in Group F. The differences
regarding glomerular necrosis, calcification, fibrosis,
giant cell reaction, adhesion, and tubular
thyroidization were confirmed significantly compared
with Group T (P < 0.001). There was no difference in
acute inflammation and fibroblast activation (P = 0.2).
Erythrocyte aggregation and microvascular
proliferation were observed to be significantly higher
in Groups G, F, and A (P < 0.001) (Figure 3A, 3B, 3C).
Discussion
Hemostasis is one of the most important technical
objectives in open partial nephrectomies for solid
renal masses smaller than 4 cm. In fact, this has
become the standard of care even in the face of a
normal contralateral kidney (13). Recently, the use of

Figure 3A. Macroview of the kidneys following traditional partial
nephrectomy with suture closure.

Figure 3B. Macroview of the kidneys following application of
Glubran 2 onto the resected kidney surface.

Figure 3C. Macroview of the kidneys following application of
FloSeal onto the resected kidney surface.

Figure 3D. Macroview of the kidneys following application of
Celox onto the resected kidney surface.

Figure 3E. Macroview of the kidneys following application of
Ankaferd onto the resected kidney surface.
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B
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Figure 4. A. The appearance of Glubran on the resected area, including minimal adhesion.
B. Good biocompatibility of FloSeal and restoration of resected tissue were observed with increased peri-renal adhesion.
C. Resorption of Celox and absence of tissue reaction were confirmed.
D. ABS kidneys, were all in good condition especially in the resected area, some redness and gelatinous, wealthy tissue.

laparoscopic techniques in PN has increased the
likelihood of hemostasis within a suitable WIT to help
preserve renal function. Hemostasis by suturing often
requires longer warm ischemia time (14). Most
investigators limited reconstruction time to 30 min,
while some felt that it could be extended to as long as
1 h (1). Bleeding and ischemic renal damage due to
prolonged warm ischemia periods are the most
important complications following the surgery (1). In
order to decrease WIT and PNT, various tissue
sealants, and hemostatic agents have been developed
to replace tissue suturing.
Studies examining the hemostatic effect of ABS on
renal surgery or renal tissue damage have been
12

performed previously (15). We confirmed that ABS
facilitated effective hemostasis with a decrease in
partial nephrectomy time and warm ischemia time in
various partial nephrectomy models (1). In addition,
erythrocyte aggregation, which is a main action
mechanism of ABS, and protein network formation
were demonstrated previously in renal hemorrhage as
in our recent study (1). The protein network induced
by ABS is formed rapidly (<1 s); however, blood cells,
particularly erythrocytes, also participate in protein
network formation. It was shown that ABS-induced
protein networks were capable of regulating further
coagulation and hemostatic reactions. Hence, regular
hemostatic processes were spared during formation
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C
Figure 5. A, B. Erythrocyte aggregation and microvascular proliferation in Group F and Group G.
C. Erythrocyte aggregation and microvascular proliferation in Group A.

of the protein network, with the blood clotting process
being driven by protein agglutination (12). The main
target of the experimental preliminary studies
regarding the efficacy of ABS on parenchymal organ
hemorrhage is to adopt the use of ABS in human
organs. We demonstrated the efficacy and safety of
ABS in a renal trauma model (15); however, decreased
hemorrhage was demonstrated in radical
prostatectomy with the application of an ABS tampon,
2.5 × 7 cm, as well (16). In one article, ABS was
successfully used in a case with upper gastrointestinal
bleeding, while, in another, therapeutic potential for
the management of hemorrhage in open heart surgery
was confirmed (1). Additionally, the Phase 1 study
stressed the safety and applicability of ABS for use in
humans.

For FDA (Food and Drug Administration)
regulation, a hemostatic agent is defined as a device
intended to produce hemostasis by accelerating the
clotting process of blood. Broadly, these agents can be
thought of as topical hemostatics, anti-fibrinolytics,
fibrin sealants, and matrix hemostats (17). The best
evidence for hemostatic use in urology comes from
renal surgery (17). In one prospectively randomized
study, 21 pigs with complex grade 4 renal injuries were
treated with FloSeal with and without preliminary
renal artery occlusion and conventional suture with
gelatin foam bolster (17). FloSeal significantly
decreased blood loss and time to hemostasis as we
demonstrated the significant less WIT and HT in
Group F. However, the histopathologic effect of
FloSeal on the renal tissue is still being debated in the
13
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literature. In particular, the application of FloSeal in
laparoscopic partial nephrectomies with significant
less blood loss and warm ischemia time was
successfully shown by Bak et al. (14). Additionally,
Gill et al. reported significantly fewer overall
complications (16% vs. 37%) in laparoscopic partial
nephrectomies using Floseal compared with a
suture/Surgicell bolster (18). Glubran® 2 (N-butyl-2cyanoacrylate) is a synthetic sealant that contains
monomers that polymerize after contact with tissue,
forming an adhesive layer with high resistance (19).
A potential advantage of synthetic sealants is that they
are not antigenic and carry no risk of viral infections
(19). The use of cyanoacrylate in the field of urology
has been achieved. As we demonstrated, the efficacy
rates of Glubran 2 application in laparoscopic partial
nephrectomies with small and wide resection were
67% and 80%, respectively (20). In our practice,
Glubran 2 offered easy preparation and application
with no need for compression and was observed to
promote significant hemostasis. Another novel
hemostatic agent, Celox®, was applied for the first time
in our rat model according to Pubmed research. The
chitosan dressing is a fairly rigid wafer that forms a
mucoadhesive physical barrier at the site of injury or
bleeding (21). According to manufacturers, it is
reportedly nonallergenic, nonexothermic, able to
function in a hypotermic environment, and low in
cost (21). We demonstrated parallel histopathologic
findings with complete resorption and without host
reaction in the renal surface. In another study, it was
demonstrated that Celox® improved hemorrhage
control and survival and was determined to be a
viable option for the treatment of severe hemorrhage
(21).
In this study, ABS was compared to licensed
hemostatic agents that provided effective hemostasis
in partial nephrectomy in evidence based medicine.
The best WIT and HT was demonstrated with
Glubran® 2 while the histopathologic and macroscopic
findings showed the adhesion and remnants of the

agent after 1 month. Despite histopathologically
significant evidence of fibrosis and adhesion, definite
improvements in HT and WIT were shown with
FloSeal; moreover, this agent has an internationally
acknowledged hemostatic effect in both open and
laparoscopic partial nephrectomies. Excellent renal
tissue surface and biocompatibility were observed in
Celox with significant effects on WIT and HT. As for
the final product, ABS demonstrated acceptable
hemostatic effect and significantly decreased WIT
and HTs with significant histopathologic findings,
without fibrosis, adhesion, or host reaction. The exact
mechanism of erythrocyte aggregation for hemostatic
action was significantly confirmed in ABS group.
Generally, each hemostatic agent provided the
predominant effect when compared with the
traditional suture technique in partial nephrectomy.
The unclear dose interval for the best hemostasis with
ABS and small size of rat kidneys were the limitations
of this study.
In this study, we aimed to compare the
histopathologic effects of hemostatic agents. In our
opinion, these agents should be considered not only
for their hemostatic properties, but also with regard
to the histopathologic effects on renal tissue.
Conclusion
This experimental study is the first trial that
compared the ABS with other hemostatic agents
licensed for internal use (FloSeal, Celox, and Glubran
2). It has been demonstrated that ABS stopped the
bleeding and decreased WIT and HT, while more
familiar findings were detected histopathologically.
However, not only the decrease in WIT and HT, but
also histopathologic biocompatibility should be
stressed as the one of the major criteria for becoming
an optimal hemostatic agent. We think that more
advanced experimental and clinical trials will improve
and clarify the optimal efficacy of ABS in renal
surgery.
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